Projects per year
Surgery first (SF) versus neoadjuvant approach (NAT) to management of potentially resectable pancreatic ductal adenocarcinoma (PDAC) is controversial. This study is unique in utilizing institutional data to offer Markov decision-analysis of overall treatment pathways for resectable PDAC.
An advanced Markov decision analysis model was constructed and populated with data from a retrospective institutional database. Patients presenting with resectable PDAC from 2008-2012 were included in the SF arm. Those presenting with resectable PDAC from 2012-2016 and treated within NAT pathway populated the NAT arm. Model uncertainties were tested with one and two-way deterministic sensitivity analysis and probabilistic Monte Carlo sensitivity analysis set to 1000 cycles with variables altered between highest and lowest observed values.
NAT pathway gave an additional 0.58 QALMs (22.43 vs. 21.85 QALMs). Monte Carlo analysis reported indifference between treatment strategies. One-way deterministic sensitivity analysis showed that probability of resection in the SF pathway must be greater than 0.82, or below 0.72 in NAT pathway, and probability of receiving adjuvant therapy above 0.6 to alter pathway superiority. Two-way deterministic sensitivity analysis demonstrated treatment superiority depended on resection rate in each pathway and receiving adjuvant therapy in SF pathway. Markov cohort analysis demonstrated superiority of neoadjuvant pathway (Table).
Optimal treatment pathway remains debatable on an intention-to-treat Markov decision analysis. Markov cohort analysis of treatment received demonstrated benefit with NAT pathway.
|Number of pages||1|
|Publication status||Published - 18 Jan 2018|
|Event||2018 Gastrointestinal Cancers Symposium: Multidisciplinary Care: Local Practice, Global Outcomes - Moscone West Building, San Francisco, United States|
Duration: 18 Jan 2018 → 20 Jan 2018
|Conference||2018 Gastrointestinal Cancers Symposium|
|Abbreviated title||ASCO GI 2018|
|Period||18/01/18 → 20/01/18|
- Markov decision analysis
- pancreatic cancer
- neoadjuvant treatment
- resectable cancer
FingerprintDive into the research topics of 'Markov decision analysis of neoadjuvant treatment pathway versus surgery first pathway for resectable pancreatic cancer'. Together they form a unique fingerprint.
- 1 Finished
1/08/16 → 31/07/19
- 1 Meeting abstract
Markov decision analysis of neoadjuvant treatment pathway versus surgery first pathway for resectable pancreatic cancerBradley, A., McKay, C. J., Jamieson, N. B., Dickson, E. J., Carter, R. & Van Der Meer, R., 26 Feb 2018, In: Journal of Clinical Oncology. 36, 4 suppl, p. 456 1 p.
Research output: Contribution to journal › Meeting abstract › peer-reviewOpen AccessFile13 Downloads (Pure)
- 1 Invited talk
Robert van der Meer (Invited speaker), Gillian Hopkins Anderson (Contributor) & Alison Bradley (Contributor)20 Aug 2018
Activity: Talk or presentation types › Invited talk